Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longeveron Inc (NQ: LGVN ) 3.290 +0.040 (+1.23%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Longeveron Inc < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Why Longeveron (LGVN) Shares Are Falling Sharply December 21, 2023 Longeveron Inc (NASDAQ: LGVN) shares are trading lower by 22.8% to $1.25 Thursday morning after the company has finalized an agreement for a Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session December 20, 2023 Via Benzinga Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer’s Disease With Lomecel-B™ December 06, 2023 --News Direct-- Via News Direct 12 Health Care Stocks Moving In Tuesday's After-Market Session December 05, 2023 Via Benzinga Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ December 05, 2023 Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress. Via Benzinga Earnings Preview: Longeveron November 09, 2023 Via Benzinga Earnings Preview: Longeveron August 10, 2023 Via Benzinga Earnings Scheduled For November 10, 2023 November 10, 2023 Companies Reporting Before The Bell • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. Via Benzinga Nearly A Third Of Japan’s 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron’s (NASDAQ: LGVN) Cell Therapy Help? October 24, 2023 --News Direct-- Via News Direct Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help? October 23, 2023 Nations all over the world are getting older, but Japan is leading the charge, with nearly a third of its total population over 65 — making Japan the oldest society in the world. Via Benzinga Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial October 13, 2023 Wa’el Hashad, CEO of Longeveron (NASDAQ: LGVN), was a guest recently on Benzinga’s All-Access. Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 12, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session October 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session October 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session October 06, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session October 05, 2023 Via Benzinga Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session October 05, 2023 Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... Via Benzinga Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study October 05, 2023 Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session September 15, 2023 Via Benzinga Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved" September 14, 2023 BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions... Via Benzinga Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market September 12, 2023 --News Direct-- Via News Direct Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market September 11, 2023 Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However,... Via Benzinga Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For September 07, 2023 --News Direct-- Via News Direct Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For September 06, 2023 Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... Via Benzinga Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session August 31, 2023 Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer... Via Benzinga US Stocks Rise; Initial Jobless Claims Edge Lower August 31, 2023 U.S. stocks traded higher this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded up 0.26% to 34,982.42 while the NASDAQ rose 0.48% to 14,086.54.... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Thursday's Pre-Market Session August 31, 2023 Via Benzinga As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs August 29, 2023 Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Via Benzinga Earnings Scheduled For August 11, 2023 August 11, 2023 Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. Via Benzinga Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 08, 2023 --News Direct-- Via News Direct < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.